AstraZeneca’s Phase III Study on Advanced Liver Cancer: A Potential Game-Changer?

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca is conducting a Phase III study titled A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma. The study aims to evaluate the efficacy and safety of rilvegostomig combined with bevacizumab, with or without tremelimumab, compared to atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma (HCC) who cannot undergo curative or locoregional therapy.

The study tests two experimental interventions: one combining rilvegostomig, bevacizumab, and tremelimumab, and another combining rilvegostomig and bevacizumab. The active comparator involves atezolizumab and bevacizumab. All treatments are administered via intravenous therapy, targeting improved outcomes in advanced HCC.

This interventional study is randomized with a parallel assignment and single masking for outcomes assessors. Its primary purpose is treatment-focused, with a safety lead-in phase to assess the combination’s tolerability before full randomization.

The study began on May 6, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on July 1, 2025, indicating ongoing recruitment.

This study could significantly impact AstraZeneca’s market position, potentially boosting investor confidence and stock performance if successful. The competition in the oncology sector remains fierce, with advancements in HCC treatment being closely watched by investors.

The study is currently ongoing, with further details available on the ClinicalTrials portal.